Table 4.

Effect of Time to NSAID on Flare Duration (in Weeks) for Early NSAID-Treated Flares (Number of Patients = 36, Number of Flares = 36)

	Unadjusted model		Adjusted for demographic/disease and treatment variables		Adjusted only for covariates with p < 0.20
	B	95% CI	B	95% CI	B	95% CI
Time to NSAID (days)a	0.18*	0.03–0.33	0.15	−0.01–0.32	0.17*	0.03–0.31
Age (years) at PANS flare			−0.06	−0.59–0.48
Sex (male/female)			−0.94	−3.83–1.95
Weeks since onset of PANS illness			0	−0.02–0.01
Previous flare treated with aggressive immunomodulatory therapyb			−1.07	−5.99–3.85
Patient on prophylactic antibiotics at onset of flare			0.18	−2.97–3.33
Antibiotics used to treat infection during flarec			2.52	−0.21–5.25	2.64*	0.28–5.00
Oral corticosteroids given during flare			0.27	−2.70–3.23
Number of psychiatric medications during flare			1.40	−1.23–4.03
Cognitive behavioral therapy during flare			0.66	−3.01–4.33

^aNumber of days from flare onset to NSAID initiation.

^bHigh-dose IVIG, intravenous methylprednisolone pulse(s) (30 mg/kg), or plasma exchange.

^cCommon infections treated during flare include group A Streptococcus, sinusitis, otitis media, Mycoplasma pneumoniae, etc.

^*p < 0.05

Results are from a standard general linear model with no repeated observations; the unstandardized B value is interpreted as the expected change in flare duration, with a one-unit change in the independent variable. For example, in the final model, for every day that NSAID initiation is delayed, the flare duration increases by 0.17 weeks. For categorical variables, the second category is the reference.